October 2024

• All the links have been checked and are working properly.

• ​There were no changes to the number of clinical trials since the previous update.

• Bocodepsin (OKI-179) was added to the Phase 2 table. 
   

August 2024

• All the links have been checked and are working properly.

  • Marizomib (Salinosporamide A; NPI-0052) : US clinical trials from 1 to 0, Europe clinical trials from 1, but appears to be completed in 2022.The compound is no longer on the Bristol Myers Squibb pipeline, so has been removed from Phase 2. https://www.bms.com/researchers-and-partners/in-the-pipeline.html . 

​

June 2024

• All the links have been checked and are working properly.

•  Plitidepsin was removed from Phase II as its development as an antiviral agent has been terminated

• The number of clinical trials have been updated accordingly​

  • CAB-AXL (BA-3011, Mecbotamab vedotin): Change “[2+]” to “[3+]” under US – Active Clinical Trials.

  • Ladiratuzumab vedotin (SGN-LIV1A): Change “[Seagen]” to “[Pfizer]” under Company/Institution: Link (https://www.seagen.com/science/pipeline) redirects to https://www.pfizer.com/science/drug-product-pipeline ; Pfizer acquired Seagen in December 2023

  • Plitidepsin: Change “[1+]” to “None” under US – Active Clinical Trials (Trial was terminated in April). Change “[1+]” to “[2+]” under Europe – Active Clinical Trials. Change [Link] under Europe – Active Clinical Trials

  • CAB-ROR2 (BA-3021, Ozuriftamab vedotin): Change “[2+]” to “[3+]” under US – Active Clinical Trials

  • Ecubectedin (PM14): Change “[2+]” to “[1+]” under US – Active Clinical Trials

  • STI-6129: Change [Link] under Company/Institution

  • ARX-517: Remove from Phase 2 (AmbRx only shows it at Phase 1 at the moment, and the only active trial is Phase 1)

  • Upifitamab rilsodotin (XMT-1536): Change “[2+]” to “[1+]” under Europe – Active Clinical Trials​

​

April 2024

• All the links have been checked and are working properly.

• CX-2029 (ABBV-2029): has been removed as there are no US Active Clinical Trials

• The number of clincal trials have been updated accordingly ​

  • ARX-788: clinical trials have been consolidated from Phase 2 to Phase 3.

  • BT8009: clinical trials have been consolidated from Phase 2 to Phase 3.

  • MRG003: clinical trials have been consolidated from Phase 2 to Phase 3.

  • Telisotuzumab vedotin (ABBV-399): clinical trials have been consolidated from Phase 2 to Phase 3.  

  • Tetrodotoxin: clinical trials have been consolidated from Phase 3 to Phase 2. Chinese clinical trials from 0 to 1.

  • STRO-002:  clinical trials have been consolidated from Phase 1 to Phase 2.

  • FOR-46: clinical trials have been consolidated from Phase 1 to Phase 2

  • ARX-517: clinical trials have been consolidated from Phase 1 to Phase 2

  • RC-88: clinical trials have been consolidated from Phase 1 to Phase 2.

  • STI-6129: clinical trials have been consolidated from Phase 1 to Phase 2

  • Farletuzumab ecteribulin (MORAb-202): clinical trials have been consolidated from Phase 1 to Phase 2

  • Upifitamab rilsodotin (XMT-1536): “[1+]” to “[2+]” under Europe-Active Clinical Trials and have been consolidated from Phase 1 to Phase 2

  • A-166 Changed “[2+]” to “[1+]” under US – Active Clinical Trials. clinical trials have been consolidated from Phase 1 to Phase 2

​

February 2024

• All the links have been checked and are working properly.

• CX-2029 (ABBV-2029): has been removed as there are no US – Active Clinical Trials

• The number of clinical trials was updated accordingly:​

  • Bryostatin: will be moved to Phase I : a  new Phase I trial to start Feb 2024 [Link]

  • MRG003: Changed “[5+]” to “[4+]” under US – Active Clinical Trials

  • RC-88: Changed “[3+]” to “[4+]” under US – Active Clinical Trials

  • ARX-788” Changed “[6+]” to “[7+]” under US – Active Clinical Trials

  • BT8009: Changed “[1+]” to “[2+]” under US – Active Clinical Trials

  • Ladiratuzumab vedotin (SGN-LIV1A): Changed “[4+]” to “[3+]” under US – Active Clinical Trials

​

​December 2023​

• All the links have been checked and are working properly.

• The number of clinical trials was updated accordingly:

  • Telisotuzumab vedotin (ABBV-399): Changed “[4+]” to “[6+]” under US – Active Clinical Trials

  • Upifitamab rilsodotin (XMT-1536): Changed “[3+]” to “[1+]”.

  • Most recently, the FDA paused Upifitamab rilsodotin trials: FDA Pauses Upifitamab Rilsodotin Trials in Platinum-Sensitive Ovarian Cancer (cancernetwork.com)

  • Plitidepsin: [Link] under Company/Institution has been updated.

​​​

October 2023

• The number of current clinical trials was updated accordingly:

  • ​MRG003: [6+] to [5+] under US-Active Clinical Trial

  • A-166: [3+] to [2+] under US-Active Clinical Trial

• ​Ecubectedin (PM14) was added

​

August 2023

• All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly:

  • MORAb-202: [2+] to [3+] under Europe – Active Clinical Trials

  • BT5528 & BT8009: Studies for both are categorized under Phase 1 AND 2 per clinicaltrials.gov and company's website. Both compounds added to Phase 2 table.

​​

June 2023

• All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly:

  • RC-88: [2+] to [3+] under US – Active Clinical Trials​

• Plocabulin (PM184) was removed as there are currently no active trials.

​

April 2023

•  All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly:

  • ​​Ladiratuzumab vedotin (SGN-LIV1A): [5+] to [4+] under US – Active Clinical Trials
  • Bryostatin: [1+] to None under US – Active Clinical Trials
  • MORAb-202: [2+] to [3+] under US – Active Clinical Trials; None to [2+] under Europe – Active Clinical Trials
  • MRG003: [5+] to [6+] under US – Active Clinical Trials
  • RC-88: [1+] to [2+] under US – Active Clinical Trials
  • STI-6129: [4+] to [5+] under US – Active Clinical Trials
  • ARX-788: None to [1+] under Europe – Active Clinical Trials
  • Upifitamab rilsodotin (XMT-1536): [2+] to [3+] under US – Active Clinical Trials; None to [1+] under Europe – Active Clinical Trials

 

February 2023

• All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly.

• Compound name and molecular target has been updated for MORAb-202

• Link has been added for chemical class for XMT-1536
   

December 2022

• All the links have been checked and were working properly, except links addressing compounds in Chinese clinical trials. We are working with Dr. Jinbo Yang's group to update these links.

• The number of current clinical trials was updated accordingly.

• Links have been added for chemical class for several compounds.

• Link has been added for compound name for MRG003

• 4 new compounds were added: RC-88, STI-6129, ARX-788, and Upifitamab rilsodotin (XMT-1536).

​

September 2022

• During September copyright notices were posted on the top and bottom of this page. Date of the last update has been edited. All the links have been checked and were working properly.

• GTS-21 was removed as currently there are no clinical trials and no institutional support for further development.  

• Telisotuzumab vedotin (ABBV-399) has 4 US clinical trials (https://clinicaltrials.gov/ct2/results?term=abbv399&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt ).

• CAB-ROR2 (BA-3021, Ozuriftamab Vedotin) has a new active European clinical trial (https://www.clinicaltrialsregister.eu/ctr-search/search?query=Ozuriftamab+Vedotin&status=ongoing).  

• BA-3011 (Mecbotamab Vedotin) has a new active European clinical trial (https://www.clinicaltrialsregister.eu/ctr-search/search?query=Mecbotamab+Vedotin&status=ongoing) and has been added to the Phase 2 page.

• MORAb-202 (Farletuzumab Ecteribulin) has a US Active Phase 2 trial (https://www.clinicaltrials.gov/ct2/show/NCT04300556?recrs=abdf&cond=MORAb-202&draw=2&rank=2) and has been moved to the Phase 2 webpage.

• MRG003 has 5 US Active Phase 2 trials (https://clinicaltrials.gov/ct2/results?cond=mrg003&term=&cntry=&state=&city=&dist=&Search=Search) and has been moved to the Phase 2 webpage.

• A-166 has 2 US Active Phase 2 trials (https://clinicaltrials.gov/ct2/show/NCT05346328?cond=A-166&draw=2&rank=3) and has been moved to the Phase 2 webpage. ​​